Precision Medicine for Hematological Tumors

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: closed (15 July 2023) | Viewed by 113

Special Issue Editors

Department of Hematology, The Second Xiangya Hospital, Molecular Biology Research Center, School of Life Sciences, Hunan Province Key Laboratory of Basic and Applied Hematology, Central South University, Changsha 410011, China
Interests: molecular mechanisms of hematopathogenesis; acute lymphoblastic leukemia; lymphoma
Department of Hematology, The Second Xiangya Hospital, Molecular Biology Research Center, School of Life Sciences, Hunan Province Key Laboratory of Basic and Applied Hematology, Central South University, Changsha 410011, China
Interests: hematopoietic stem cells; epigenetic regulations; leukemia stem cells; acute myeloid leukemia
Department of Hematology, The Second Xiangya Hospital, Molecular Biology Research Center, School of Life Sciences, Hunan Province Key Laboratory of Basic and Applied Hematology, Central South University, Changsha 410011, China
Interests: molecular mechanisms of hematopathogenesis; hereditary hematological disorders; T-cell acute lymphoblastic leukemia

Special Issue Information

Dear Colleagues,

Hematological tumors are blood tumors with complex heterogeneity. Previous morphology was used to classify the disease categories. Due to improvements in technology, especially the next-generation sequence, precise gene mutations and chromosome translocations are identified. People found that different abnormalities have specific mechanisms to promote the development of hematological tumors. Nowadays, molecular abnormalities are widely accepted to classify the disease categories. Based on the molecular mechanisms, many drugs and therapeutic methods are developed. The most successful one is the tyrosine kinase inhibitor (TKI). The TKI targets the BCR-ABL fusion gene which drives chronic myeloid leukemia (CML) development. The CML patients receiving TKI treatment could be expected to have a survival instinct and quality of life of the age-matched healthy people. Besides the TKI, gilteritinib (target FLT3-ITD mutation), venetoclax (target BCL-2), and other inhibitors are under development; chimeric antigen receptor T-cells (CAR-T cells), antibodies, gene editing, and other methods are created. These drugs and methods completely changed treatment strategies of hematological tumor. The therapies goes into the era of personalized treatment.

In this Special Issue, we aim to focus on the precision medicine for hematological tumors, original research articles and review articles are welcome.

Prof. Dr. Hongling Peng
Dr. Yue Sheng
Dr. Zhao Cheng
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hematological tumors
  • precision medicine
  • targeted drugs
  • therapeutic methods
  • personalized treatment
  • gene mutations
  • molecular mechanisms

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop